Producing Scientific Breakthroughs for the Diagnosis of Triple Negative Breast Cancer
We have identified a novel molecular target for Triple Negative Breast Cancer, which is:
Directly involved in DNA replication/proliferation.
Endocrine and growth receptor independent.
Unique molecular target for the detection of Triple negative breast cancer.
Our molecular target will offer the following benefits over the currently existing cancer diagnostics:
Ideal molecular target for Triple Negative Breast Cancer.
A global molecular target for all subtypes of breast cancer.
Will function as a universal molecular target for cancer detection of other gynecological, such as ovarian, uterine and cervical cancers.
A non-invasive diagnostic tool for blood cancers such as acute and chronic myelo cancersid leukemia.
Novel early diagnostic molecular target for the progression of cancer.
Will function as prognosis/predictive marker of cancer.
No more finding a needle in the haystack. We already found it.
Precision molecular target with predictive pathway-will overcome issues of physician doubt and payers reluctance.
We have designed a unique technology for detection of the message of our molecular target from three different primary human breast cancer cell lines and we are currently developing a multiplex PCR kit for Triple Negative Breast Cancer.
